Kurma Partners Closes Biofund IV at $236M, Delivering Fresh Biotech Capital

Why It Matters

Biofund IV provides a fresh, focused capital pool for European biotech founders while signaling that disciplined, strategy‑driven funds can still attract LP money in a cautious market.

Key Takeaways

• Kurma's Biofund IV closed at €215 M (~$232 M), below €250 M target
• Fund aims to back 16‑20 biotech firms, 80% in therapeutics
• Early investments include Memo Therapeutics, Avidicure, EvlaBio, Nuevocor, Elkedonia
• Kurma's track record features $1.05 B Amolyt exit, boosting LP confidence
• European biotech fundraising remains disciplined despite improving market conditions

Pulse Analysis

European biotech venture capital has entered a nuanced phase, where specialist funds like Kurma Partners’ Biofund IV must balance ambition with market realism. Closing at €215 million (about $232 million), the fund is modest compared with the €250 million goal but remains one of the larger dedicated biotech vehicles in Europe. This reflects a broader trend: after the post‑2021 correction, limited partners are selective, rewarding firms that demonstrate a clear thesis, strong networks, and a track record of exits. Kurma’s ability to secure a respectable pool signals confidence in its differentiated approach amid a disciplined capital environment.

The fund’s investment strategy is tightly focused on therapeutic innovation, allocating roughly 80% of capital to companies developing new treatments for high‑unmet‑need diseases. Kurma’s hands‑on model—spanning company creation, spin‑out support, and later‑stage follow‑on funding—positions it as more than a financial backer. Early deployments illustrate this: Memo Therapeutics secured a CHF 45 million (≈$49 million) Series C, Avidicure raised a $50 million seed, and subsequent rounds for EvlaBio (€21 million ≈ $23 million), Nuevocor ($45 million), Elkedonia (€11.25 million ≈ $12 million) and Laigo Bio (€17 million ≈ $18 million) showcase the fund’s breadth across Europe and beyond. These investments underscore Kurma’s commitment to nurturing companies from academic discovery through clinical proof of concept.

Kurma’s credibility is further bolstered by Biofund III’s marquee exits, most notably the $1.05 billion acquisition of Amolyt Pharma by AstraZeneca and the €46.3 million (≈$50 million) upfront payment for Corlieve Therapeutics. Such outcomes reinforce LP confidence that specialist biotech funds can deliver outsized returns despite a cautious fundraising climate. Looking ahead, Biofund IV’s portfolio is poised to benefit from Europe’s strong translational science pipeline, while Kurma’s continued emphasis on active partnership may set a benchmark for future life‑sciences funds seeking to combine capital with operational expertise.

Deal Summary

Kurma Partners announced the final close of its Biofund IV at $236 million, below its $275 million target, creating a new source of capital for European biotech founders. The fund aims to back 16‑20 companies developing therapeutic solutions, building on Kurma’s hands‑on creation model. The closure follows early investments in firms such as Memo Therapeutics and Avidicure.